New England Regional Council Offers Guidance on Effective Management of Type 2 Diabetes

December 30, 2014
Source: 
Institute For Clinical And Economic Review

Boston, MA., December 22, 2014 -The New England Comparative Effectiveness Public Advisory Council (CEPAC), a core program of the Institute for Clinical and Economic Review (ICER), has released a final evidence report, titled "Controversies in the Management of Patients with Type 2 Diabetes." The report incorporates findings from a recent public meeting of CEPAC, during which council members reviewed evidence on the effectiveness and value of add-on use of certain medications to improve diabetes control, including sulfonylureas and multiple forms of insulin, as well as two relatively new classes of medications, dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. The key findings of the report, along with CEPAC's votes, suggest that high value treatment options, such as NPH insulin (intermediate-acting human insulin), may be underutilized in many patients. 

Read ICER Press Release